
In the evolving landscape of evidence-based medicine (EBM), traditional hierarchies of evidence-anchored by randomized controlled trials (RCTs) and systematic  reviews-are  increasingly  being  challenged  by  the  emergence  of  new evidence modalities. The article 'Redefining the Hierarchy of Evidence in Medicine in the Era of the Next Generation Clinical Trials and Real-World Evidence' by El  Oakley  et  al.  offers  a  compelling  re-examination  of  how  clinical  evidence should  be  ranked  in  the  era  of  precision  medicine,  OMICS-guided  trials,  and real-world data analytics.<sup style="color:#44A6B2;">1</sup>

The authors highlight a critical limitation of conventional hierarchies such as the Oxford Centre for Evidence-Based Medicine (OCEBM) and GRADE systems: their failure to formally integrate innovative evidence sources including OMICS-guided  trials, causally interpretable meta-analyses, and  real-world evidence (RWE).<sup style="color:#44A6B2;">2,3</sup> In doing so, they present a sophisticated framework-the 'Next Generation Hierarchy of Evidence'-that proposes a novel top tier (A+) to accommodate rigorously validated OMICS-guided and propensity-matched real-world data recognized by regulatory authorities such as the FDA and EMA.<sup style="color:#44A6B2;">4,5</sup>

This redefined framework arrives at a pivotal time. Regulatory agencies have increasingly acknowledged the legitimacy of RWE and OMICS-based approaches, particularly in oncology and rare diseases, where traditional RCTs are often infeasible  or  ethically  challenging.<sup style="color:#44A6B2;">6,7</sup> The  FDA's  approval  of  several  therapies based on real-world evidence and surrogate endpoints exemplifies this paradigm  shift,  underscoring  the  urgency  for  a  hierarchy  that  reflects  these  new evidence realities.<sup style="color:#44A6B2;">8</sup>

The proposed four-tier hierarchy (A+, A, B, C) and its sixteen sublevels mark a significant  advancement  over  the  traditional  pyramid  model.<sup style="color:#44A6B2;">9</sup>  It  introduces greater granularity by accounting for study multiplicity, causal inference capability, regulatory recognition, and reproducibility. Particularly notable is the explicit acknowledgment of causal meta-analysis (CMA) as a higher evidential standard than conventional meta-analysis-a recognition that aligns with modern advances in causal inference theory.<sup style="color:#44A6B2;">10,11</sup>

By integrating emerging  modalities, this  framework  bridges  the  gap between precision research and guideline development. It complements the GRADE  framework  rather  than  replacing  it,  offering  a  dynamic  model  that remains adaptable to evolving technologies and data ecosystems.<sup style="color:#44A6B2;">12</sup> Importantly, it  encourages harmonization between clinical research, regulatory policy, and patient-centered outcomes-a crucial triad for next-generation healthcare.<sup style="color:#44A6B2;">13</sup>

However, this shift demands caution. While OMICS and RWE expand evidentiary  inclusivity,  they  also  raise  new  methodological  concerns  regarding  bias, data harmonization, and reproducibility.<sup style="color:#44A6B2;">14,15</sup> The transition to a next-generation hierarchy must therefore be guided by methodological rigor, transparent reporting, and multidisciplinary oversight to preserve the core tenets of EBM: validity, reliability, and applicability.<sup style="color:#44A6B2;">16</sup>

The proposed Next Generation Hierarchy of Evidence represents an inflection point for modern clinical science. It not only acknowledges the evolving landscape  of  biomedical  data  but  also  reimagines  how evidence should be synthesized, graded, and applied in practice. As precision medicine and AI-driven analytics continue to transform research, frameworks like this will be instrumental in ensuring that evidence-based medicine remains both attainable and scientifically relevant.<sup style="color:#44A6B2;">17,18</sup>

This editorial commends the authors' vision and the pragmatic inclusivity of their proposal. By incorporating OMICS-guided evidence, causal meta-analysis, and RWE within  a  structured  hierarchy,  their  work  provides  an essential  foundation  for  the  future  of  evidence-based decision-making. It bridges the widening gap between classical  evidence  hierarchies  and  the  complexities  of modern biomedical research-paving the way toward a more  responsive,  data-integrated,  and  patient-centric model of evidence-based medicine.

###### References

1. El Oakley R, Elmuttardi K, Altawaty A, et al. Redefining the hierarchy of evidence in medicine in the era of the next generation clinical trials and real world evidence: a critical review and the next generation hierarchy. J Best Avail Evid Med. 2025;1(2):25-29
2. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). Journal of Clinical Epidemiology. 2011;64(4):407-415. doi: 10.1016/j.jclinepi.2010.07.017
3. Oxford Centre for Evidence-Based Medicine. Levels of evidence (March 2009). 2011.
4. U.S. Food and Drug Administration. Framework for FDA's real-world evidence program. 2019.
5. European Medicines Agency. Guideline on registry-based studies. 2020. doi: 10.12659/MSM.933554
6. Makady A, de Boer A, Hillege H, Klungel O, Goettsch W. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value in Health. 2017;20(7):858-865. doi: 10.1016/j.jval.2017.03.008 6.
7. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, Califf RM. Real-world evidence - what is it and what can it tell us? New England Journal of Medicine. 2016;375(23):2293-2297. doi: 10.1056/NEJMsb1609216 7.
8. Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867-868. doi: 10.1001/jama.2018.10136 8.
9. Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. BMJ Evidence-Based Medicine. 2016;21(4):125-127. doi: 10.1136/ebmed-2016-110401 9.
10. Pearl J, Mackenzie D. The book of why: The new science of cause and effect. 2018. doi:10.56645/jmde.v14i31.507 10.
11. Hernán MA, Robins JM. Causal inference: What if. 2020. doi: 10.1111/biom.13321 11.
12. Schünemann HJ, Brożek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. 2019. 12.
13. Concato J, Corrigan-Curay J, Wang SV. Real-world evidence: Pragmatic trials and regulatory considerations. Clinical Trials. 2021;18(4):473-481. doi: 10.1056/NEJMp2200089 13.
14. Makady A, Goettsch W. Review of regulatory guidance for the use of real-world evidence for pharmaceutical approvals. Pharmacoeconomics. 2018;36(12):1393-1403. 14.
15. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018;35(11):1763-1774. doi: 10.1007/s12325-018-0805-y 15.
16. Ioannidis JPA. Why most clinical research is not useful. PLoS Medicine. 2016;13(6):e1002049. doi: 10.1371/journal.pmed.1002049 16.
17. Topol E. Deep medicine: How artificial intelligence can make healthcare human again. 2019. 17.
18. Collins FS, Varmus H. A new initiative on precision medicine. New England Journal of Medicine. 2015;372(9):793-795. doi: 10.1056/NEJMp1500523 18.